Explanipedia

Assessing the distribution of cancer stem cells in tumorspheres Open

Jerónimo Fotinós, María Paula Marks, Lucas Barberis, Luciano Vellón · 2024

Assessing the distribution of cancer stem cells in tumorspheres Open

Jerónimo Fotinós, María Paula Marks, Lucas Barberis, Luciano Vellón · 2024

In previous theoretical research, we inferred that cancer stem cells (CSCs), the cells that presumably drive tumor growth and resistance to conventional cancer treatments, are not uniformly distributed in the bulk of a tumorsphere. To conf…

Assessing the distribution of cancer stem cells in tumorspheres Open

Jerónimo Fotinós, María Paula Marks, Lucas Barberis, Luciano Vellón · 2024

In previous theoretical research, we inferred that cancer stem cells (CSCs), the cells that presumably drive tumor growth and resistance to conventional cancer treatments, are not uniformly distributed in the bulk of a tumorsphere. To conf…

Role of hydroxymethylglutharyl-coenzyme A reductase in the induction of stem-like states in breast cancer Open

María Paula Marks, Carla Alejandra Giménez, Luciana Isaja, Mariana Belén Vera, Francisco Raúl Borzone , et al. · 2024

Purpose De novo synthesis of cholesterol and its rate-limiting enzyme, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMGCR), is deregulated in tumors and critical for tumor cell survival and proliferation. However, the role of HMGCR in…

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models Open

María Jimena Rodriguez, María Cecilia Perrone, Marina Riggio, Marta Palafox, Valeria Salinas , et al. · 2023

Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel …

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models. Open

María Jimena Rodriguez, María Cecilia Perrone, Marina Riggio, Marta Palafox, Valeria Salinas , et al. · 2022

Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel …

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α6β1 drives endocrine resistance in breast cancer cells Open

Ingrid Espinoza, Lin Yang, Travis Vander Steen, Luciano Vellón, Elisabet Cuyàs , et al. · 2022

CCN1/CYR61 promotes angiogenesis, tumor growth and chemoresistance by binding to its integrin receptor α_vβ₃ in endothelial and breast cancer (BC) cells. CCN1 controls also tissue regeneration by engaging its integrin …

Understanding the influence of substrate when growing tumorspheres Open

Lucía Benítez, Lucas Barberis, Luciano Vellón, C. A. Condat · 2021

Background Cancer stem cells are important for the development of many solid tumors. These cells receive promoting and inhibitory signals that depend on the nature of their environment (their niche) and determine cell dynamics. Mechanical …

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer Open

Javier A. Menéndez, Adriana Papadimitropoulou, Travis Vander Steen, Elisabet Cuyàs, Bharvi P. Oza-Gajera , et al. · 2021

The identification of clinically important molecular mechanisms driving endocrine resistance is a priority in estrogen receptor-positive (ER+) breast cancer. Although both genomic and non-genomic cross-talk between the ER and growth factor…

Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer Open

Javier A. Menéndez, Susan K. Peirce, Adriana Papadimitropoulou, Elisabet Cuyàs, Travis Vander Steen , et al. · 2020

Progesterone receptor (PR) isoforms can drive unique phenotypes in luminal breast cancer (BC). Here, we hypothesized that PR-B and PR-A isoforms differentially modify the cross-talk between prolactin and fatty acid synthase (FASN) in BC. W…

Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer Open

Adriana Papadimitropoulou, Luciano Vellón, Ella Atlas, Travis Vander Steen, Elisabet Cuyàs , et al. · 2020

Sustained HER2/HER3 signaling due to the overproduction of the HER3 ligand heregulin (HRG) is proposed as a key contributor to endocrine resistance in estrogen receptor-positive (ER+) breast cancer. The molecular mechanisms linking HER2 tr…

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer Open

Javier A. Menéndez, Inderjit Mehmi, Adriana Papadimitropoulou, Travis Vander Steen, Elisabet Cuyàs , et al. · 2020

HER2 transactivation by the HER3 ligand heregulin (HRG) promotes an endocrine-resistant phenotype in the estrogen receptor-positive (ER+) luminal-B subtype of breast cancer. The underlying biological mechanisms that link them are, however,…

Understanding the Influence of Substrate When Growing Tumorspheres Open

Lucía Benítez, Lucas Barberis, Luciano Vellón, C. A. Condat · 2020

Background: Cancer stem cells are important for the development of many solid tumors. These cells receive promoting and inhibitory signals that depend on the nature of their environment (their niche) and determine cell dynamics. Mechanical…

An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors Open

Sara Verdura, Elisabet Cuyàs, Jesús Lozano‐Sánchez, Cristian Bastidas-Velez, Laura Llorach-Parés , et al. · 2018

Mutations in the isocitrate dehydrogenase 1 (IDH1) gene confer an oncogenic gain-of-function activity that allows the conversion of α-ketoglutarate (α-KG) to the oncometabolite R-2-hydroxyglutarate (2HG). The accumulation of 2HG inhibits α…

Noncoding RNAs and Base Modifications: Epigenomic Players Implicated in Neurological Disorders and Tumorigenesis Open

Yujing Li, Changwon Park, Hong Jiang, Xuekun Li, Luciano Vellón · 2018

Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Open

Bruna Corominas-Faja, Luciano Vellón, Elisabet Cuyàs, María Buxó, Begoña Martı́n-Castillo , et al. · 2017

Fatty acid synthase (FASN) is a key lipogenic enzyme for de novo fatty acid biosynthesis and a druggable metabolic oncoprotein that is activated in most human cancers. We evaluated whether the HER2-driven lipogenic phenotype might represen…

The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells Open

Javier A. Menéndez, Luciano Vellón, Ingrid Espinoza, Ruth Lupu · 2016

The angiogenic inducer CCN1 (Cysteine-rich 61, CYR61) is differentially activated in metastatic breast carcinomas. However, little is known about the precise mechanisms that underlie the pro-metastatic actions of CCN1. Here, we investigate…

iPSCs: From Bench to Clinical Bed Open

Yujing Li, Changwon Park, Luciano Vellón, Xuekun Li · 2016

Heregulin, a new interactor of the telosome/shelterin complex in human telomeres Open

Javier A. Menéndez, Louisa Benboudjema, Luciano Vellón, Miguel A. Rubio, Ingrid Espinoza , et al. · 2015

Telomere length, shape and function depend on a complex of six core telomere-associated proteins referred to as the telosome or shelterin complex. We here demonstrate that the isoform β2 of the heregulin family of growth factors (HRGβ2) is…

Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling Open

Javier A. Menéndez, Barbara Schroeder, Susan K. Peirce, Luciano Vellón, Adriana Papadimitropoulou , et al. · 2015

These findings reveal that an essential "activating" sequence exists in the extracellular domain of HER2. Disruption of this sequence disables the HER2 dimerization loop, blocks subsequent activation of HER2-driven oncogenic signaling, and…

Luciano Vellón YOU? Author Swipe